SCHEMBL20161764

SCHEMBL20161764

Cn1c(=O)c2c(ncn2CC(=O)NCCc2ccccc2)n(C)c1=O

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.71
CYP3A4 P08684 1/20 0.71
ALDH1A1 P00352 3/20 0.67
LMNA P02545 2/20 0.67
GAA P10253 1/20 0.67
MAPK1 P28482 2/20 0.66
RXFP1 Q9HBX9 2/20 0.66
TP53 P04637 1/20 0.66
TSHR P16473 1/20 0.65
HSD17B10 Q99714 2/20 0.64
ADORA2B P29275 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
ALOX15 P16050 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18166590 0.94 CYP1A2 (0.69) CYP1A2CYP3A4ALDH1A1LMNAGAA
SCHEMBL18166647 0.92 CYP1A2 (0.66) CYP1A2CYP3A4ALDH1A1LMNAGAA
SCHEMBL18166663 0.91 CYP1A2 (0.71) CYP1A2CYP3A4LMNAGAAMAPK1
SCHEMBL1060801 0.90 CYP1A2 (0.72) CYP1A2CYP3A4LMNAGAAMAPK1
SCHEMBL18166736 0.90 CYP1A2 (0.72) CYP1A2CYP3A4ALDH1A1LMNAGAA
SCHEMBL1066761 0.89 CYP1A2 (0.71) CYP1A2CYP3A4LMNAGAAMAPK1
SCHEMBL18166737 0.89 CYP1A2 (0.71) CYP1A2CYP3A4ALDH1A1LMNAGAA
SCHEMBL18166730 0.89 PDE4A (0.62) CYP1A2CYP3A4ALDH1A1LMNAGAA
SCHEMBL1060574 0.89 CYP1A2 (0.70) CYP1A2CYP3A4LMNAGAAMAPK1
SCHEMBL18166555 0.89 CYP1A2 (0.70) CYP1A2CYP3A4LMNAGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 CYP1A2 1369/4885CYP3A4 2805/4885ALDH1A1 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.